AC
IPXL

Apex Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Apex Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-368,600
Closed -$7.54M – 82
2013
Q3 		$7.54M Sell
368,600
-1,116,400
-75% -$23.1M 0.54% 60
2013
Q2 		$29.6M Buy
+1,485,000
New +$26.4M 2.02% 15

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Apex Capital's IPXL Position: Q4 2013 in Review

Apex Capital sold out of Impax Laboratories, Inc. (IPXL) in Q4 2013, closing a stake of 368,600 shares — an estimated $7.54M sold.

Apex Capital first reported a position in IPXL in Q2 2013 and held it in 2 quarters. The position peaked at $29.6M in Q2 2013. 166 funds tracked by Wall St. Rank hold IPXL as of Q4 2013.

  • Apex Capital reported no remaining Impax Laboratories, Inc. position as of Q4 2013 after selling out during the quarter.
  • Apex Capital sold 368,600 Impax Laboratories, Inc. shares in Q4 2013, an estimated $7.54M.
  • Apex Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 2 quarters.
  • Apex Capital's Impax Laboratories, Inc. position peaked at $29.6M in Q2 2013.
  • 166 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2013.

Based on Apex Capital's 13F filing for Q4 2013, filed 4 Feb 2014.